Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#81 / 120 Total
NB - NioCorp Developments Ltd - Stock Price Chart
TickerNB [NASD, RUT]
CompanyNioCorp Developments Ltd
IndustryOther Industrial Metals & Mining
Market Cap101.08MEPS (ttm)-1.30
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-27.39%
P/S-EPS next 5Y-
P/B-EPS Q/Q-0.65%
Dividend-Sales Q/Q-
Insider Own7.36%Inst Own4.53%
Insider Trans0.00%Inst Trans-
Short Float1.99%Earnings-
Analyst Recom-Target Price-
Avg Volume147.47K52W Range3.03 - 11.02
NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Southeast Nebraska for the production of niobium, scandium, and titanium. The company was founded on February 27, 1987 and is headquartered in Centennial, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Honan ScottChief Operating OfficerNov 15Option Exercise3.9335,000137,70489,452Nov 17 04:30 PM
Shah Neal S.Chief Financial OfficerNov 15Option Exercise3.9335,000137,70490,000Nov 17 04:30 PM
BELING DAVID COATESDirectorNov 15Option Exercise3.9330,000118,032100,891Nov 17 04:31 PM
Wightman Anna CastnerDirectorNov 15Option Exercise3.9330,000118,03259,362Nov 17 04:30 PM
MESO - Mesoblast Ltd ADR - Stock Price Chart
CompanyMesoblast Ltd ADR
Market Cap223.78MEPS (ttm)-0.53
P/E-EPS this Y22.92%
Forward P/E-EPS next Y6.10%
PEG-EPS past 5Y-7.89%
P/S29.03EPS next 5Y48.80%
P/B0.38EPS Q/Q10.99%
Dividend-Sales Q/Q-3.91%
Insider Own-Inst Own0.66%
Insider Trans-Inst Trans12.45%
Short Float0.45%EarningsAug 30/a
Analyst Recom1.80Target Price2.03
Avg Volume137.90K52W Range1.09 - 5.12
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
WINT - Windtree Therapeutics Inc - Stock Price Chart
CompanyWindtree Therapeutics Inc
Market Cap4.51MEPS (ttm)-19.81
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y55.63%
P/S-EPS next 5Y-
P/B0.60EPS Q/Q86.80%
Dividend-Sales Q/Q-
Insider Own21.67%Inst Own4.04%
Insider Trans0.45%Inst Trans100.93%
Short Float1.24%EarningsNov 09/a
Analyst Recom1.00Target Price5.00
Avg Volume109.15K52W Range0.86 - 19.06
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOSep 27Buy1.022,5002,55057,877Sep 28 07:24 AM
Fraser CraigPresident and CEOSep 26Buy0.902,5002,25055,377Sep 27 07:34 AM
Fraser CraigPresident and CEOApr 26Buy1.771,4972,6507,010Apr 27 07:41 AM
Fraser CraigPresident and CEOApr 25Buy1.891,3152,4855,513Apr 26 07:21 AM
NHWK - NightHawk Biosciences Inc - Stock Price Chart
CompanyNightHawk Biosciences Inc
Market Cap9.00MEPS (ttm)-2.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y39.86%
P/S4.03EPS next 5Y-
P/B0.25EPS Q/Q0.73%
Dividend-Sales Q/Q-88.03%
Insider Own13.59%Inst Own8.64%
Insider Trans0.00%Inst Trans-30.55%
Short Float1.35%EarningsNov 21/a
Analyst Recom1.00Target Price8.00
Avg Volume45.90K52W Range0.35 - 1.29
Nov-20-23 04:05PM NightHawk Biosciences Provides Q3 2023 Business Update (GlobeNewswire)
Oct-09-23 08:26AM NHWK: 2Q:23 Results (Zacks) -5.89%
Aug-24-23 08:24AM Morrisville CEO wants to acquire his company's subsidiary for $45M+ (American City Business Journals)
08:24AM Morrisville CEO pitches to buy his company's subsidiary for $45M+ (American City Business Journals)
Aug-14-23 04:05PM NightHawk Biosciences Provides Q2 2023 Business Update (GlobeNewswire)
May-19-23 10:46AM NHWK: First Scorpius Revenues (Zacks Small Cap Research)
May-15-23 04:05PM NightHawk Biosciences Provides Q1 2023 Business Update (GlobeNewswire)
Apr-11-23 08:23AM NHWK: ANTHIM Sales Boost Revenues (Zacks Small Cap Research) -6.10%
Mar-31-23 04:05PM NightHawk Biosciences Provides 2022 Year End Business Update (GlobeNewswire)
Dec-12-22 09:02AM NHWK: Shifting Focus to Biomanufacturing (Zacks Small Cap Research)
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
SRFM - Surf Air Mobility Inc - Stock Price Chart
CompanySurf Air Mobility Inc
Market Cap50.77MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.79EPS Q/Q-566.21%
Dividend-Sales Q/Q355.94%
Insider Own20.58%Inst Own9.34%
Insider Trans-0.36%Inst Trans-
Short Float1.88%EarningsNov 14/a
Analyst Recom1.33Target Price3.54
Avg Volume326.19K52W Range0.68 - 5.00
Surf Air Mobility, Inc. operates as an electric aviation and air travel company. The company was founded by Sudhin Shahani and Liam Fayed in 2021 and is headquartered in Hawthorne, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mady Edward A.DirectorJul 31Sale2.0554,914112,57495,784Aug 01 09:43 PM
YUMC - Yum China Holdings Inc - Stock Price Chart
CompanyYum China Holdings Inc
Market Cap16.53BEPS (ttm)1.86
P/E21.52EPS this Y85.18%
Forward P/E17.92EPS next Y14.68%
PEG0.60EPS past 5Y0.22%
P/S1.56EPS next 5Y36.04%
P/B2.52EPS Q/Q19.58%
Dividend1.39%Sales Q/Q8.53%
Insider Own3.12%Inst Own78.05%
Insider Trans0.06%Inst Trans0.23%
Short Float2.18%EarningsOct 31/a
Analyst Recom1.40Target Price60.82
Avg Volume2.36M52W Range39.91 - 64.70
Yum China Holdings, Inc. engages in the business of franchising and owning entities that own and operate restaurants. It operates through the following segments: Kentucky Fried Chicken (KFC), Pizza Hut, and All Other Segments. The KFC segment focuses on operating a restaurant chain. The Pizza Hut segment offers casual dining and home service. The All Other segment includes Taco Bell, Lavazza, Little Sheep, Huang Ji Huang, COFFii and JOY, East Dawning, and other e-commerce business. The company was founded in 1987 and is headquartered in Shanghai, China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang LeilaChief Technology OfficerNov 24Option Exercise21.307,534160,47418,871Nov 28 06:41 AM
Zhang LeilaChief Technology OfficerNov 24Sale45.021,79080,58617,081Nov 28 06:41 AM
Wat JoeyChief Executive OfficerNov 22Buy46.2614,000647,615269,144Nov 22 09:52 PM
Wang WartonGeneral Manager, KFCNov 21Option Exercise21.307,305155,5969,083Nov 24 08:38 AM
Wang WartonGeneral Manager, KFCNov 21Sale46.783,975185,9615,108Nov 24 08:38 AM
MAIA - MAIA Biotechnology Inc - Stock Price Chart
CompanyMAIA Biotechnology Inc
Market Cap12.55MEPS (ttm)-1.46
P/E-EPS this Y14.57%
Forward P/E-EPS next Y-6.02%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.57EPS Q/Q26.10%
Dividend-Sales Q/Q-
Insider Own36.53%Inst Own2.31%
Insider Trans0.00%Inst Trans180.62%
Short Float3.13%EarningsNov 07/b
Analyst Recom1.00Target Price12.62
Avg Volume356.96K52W Range0.90 - 5.22
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Guerrero RamiroDirectorMay 18Buy2.471,2002,964312,672May 22 06:49 AM
Luput CristianDirectorMay 15Buy2.633,0007,890298,068May 17 06:55 AM
Vitoc VladChief Executive OfficerApr 28Buy2.504,00010,000809,121May 01 06:30 AM
Smith StanDirectorApr 27Buy2.25133,300299,925686,628Apr 28 06:46 AM
Louie Ngar YeeDirectorApr 27Buy2.2548,000108,000976,584Apr 28 06:49 AM
SMWB - Similarweb Ltd - Stock Price Chart
CompanySimilarweb Ltd
IndustrySoftware - Application
Market Cap369.92MEPS (ttm)-0.53
P/E-EPS this Y92.19%
Forward P/E95.13EPS next Y182.71%
PEG-EPS past 5Y15.63%
P/S1.74EPS next 5Y-
P/B31.10EPS Q/Q77.60%
Dividend-Sales Q/Q9.62%
Insider Own66.01%Inst Own19.13%
Insider Trans0.00%Inst Trans-0.49%
Short Float1.22%EarningsNov 07/a
Analyst Recom1.43Target Price8.67
Avg Volume89.29K52W Range4.65 - 7.95
SimilarWeb Ltd. engages in the provision of digital market intelligence platform. The firm develops measuring and monitoring tools of websites, and offers browser plugins and tools to explore the web and application programming interface. The company was founded by Or Offer, Nir Cohen, and Benjamin Seror in 2007 and is headquartered in Tel Aviv, Israel.
AMPY - Amplify Energy Corp. - Stock Price Chart
CompanyAmplify Energy Corp.
IndustryOil & Gas E&P
Market Cap225.22MEPS (ttm)9.33
P/E0.62EPS this Y586.13%
Forward P/E3.45EPS next Y-82.23%
PEG0.04EPS past 5Y-
P/S0.69EPS next 5Y15.00%
P/B0.65EPS Q/Q-129.33%
Dividend-Sales Q/Q-39.22%
Insider Own2.23%Inst Own40.13%
Insider Trans-0.79%Inst Trans2.25%
Short Float2.96%EarningsNov 06/a
Analyst Recom1.00Target Price11.00
Avg Volume499.05K52W Range5.77 - 10.23
Amplify Energy Corp. is an independent oil and natural gas company, which engages in the acquisition, development, exploration, and production of oil and natural gas properties. It focuses on operations in Oklahoma, the Rockies, offshore Southern California, East Texas and North Louisiana, and Eagle Ford. The company was founded in 2011 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FREW JAMESSVP, CHIEF FINANCIAL OFFICERNov 08Buy6.0510,00060,49910,000Nov 09 04:05 PM
FURBEE DANIELSVP, CHIEF OPERATING OFFICERNov 07Buy6.1010,00060,96310,000Nov 08 04:05 PM
Adams Deborah GDirectorSep 20Buy6.9510,00069,45132,884Sep 21 04:05 PM
Snyder Todd RDirectorSep 12Buy7.442,67919,93264,339Sep 13 04:34 PM
Douglas Patrice DDirectorSep 11Sale7.137,00049,92041,218Sep 12 04:05 PM
PBLA - Panbela Therapeutics Inc. - Stock Price Chart
CompanyPanbela Therapeutics Inc.
Market Cap2.50MEPS (ttm)-200.81
P/E-EPS this Y99.50%
Forward P/E-EPS next Y69.50%
PEG-EPS past 5Y10.22%
P/S-EPS next 5Y-
P/B-EPS Q/Q98.94%
Dividend-Sales Q/Q-
Insider Own0.05%Inst Own8.88%
Insider Trans-96.60%Inst Trans-
Short Float1.27%EarningsNov 09/a
Analyst Recom1.00Target Price20.50
Avg Volume1.07M52W Range0.48 - 295.20
Dec-04-23 08:00AM Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors (GlobeNewswire) -13.30%
Nov-29-23 08:15AM Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification (GlobeNewswire)
Nov-09-23 04:10PM Panbela Provides Business Update and Reports Q3 2023 Financial Results (GlobeNewswire) -13.13%
Nov-03-23 07:55AM Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) -24.19%
Nov-02-23 08:15AM Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves Cell Function in Type 1 Diabetes (GlobeNewswire) +19.27%
Oct-31-23 08:15AM Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Oct-25-23 08:15AM Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication (GlobeNewswire)
Oct-24-23 08:15AM Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023 (GlobeNewswire)
Sep-26-23 08:15AM Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101 (GlobeNewswire)
Sep-19-23 08:15AM Panbela to Present at the LD Micro Investor Conference (GlobeNewswire)
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm's product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDMAN SACHS GROUP INC10% OwnerNov 08Sale0.7172,87451,741397,954Nov 13 07:29 PM